ArticleAntimicrobial agents and chemotherapy2002
Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro.
Article in Antimicrobial agents and chemotherapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematical Review on ART Use in HTLV Infection: Clinical, Virological, and Immunological Outcomes.Pathogens (Basel, Switzerland) · 2024Pooled it
- Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial.Retrovirology · 2006Trial
- Targeted Interventions in HAM/TSP: Emerging Therapies and Future Directions - A Narrative Review.Health science reports · 2026Article
- Cytotoxic Effects of a Triorganotin Derivative on HTLV-1-Infected Cells at Different Immortalization/Transformation Stages In Vitro.Molecules (Basel, Switzerland) · 2026Article
- Current State of Therapeutics for HTLV-1.Viruses · 2024Review
- HTLV-1 Transmission and HIV Pre-exposure Prophylaxis: A Scoping Review.Frontiers in medicine · 2022Article
- Implications of human T-lymphotropic virus in pregnancy: A case report and a review of the diagnostic criteria and management proposal.Experimental and therapeutic medicine · 2021Article
- Antiretroviral Therapy in HTLV-1 Infection: An Updated Overview.Pathogens (Basel, Switzerland) · 2020Review
- Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma.Frontiers in microbiology · 2018Review
- How to Control HTLV-1-Associated Diseases: PreventingFrontiers in microbiology · 2018Article
- Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-α.Blood advances · 2017Article
- Susceptibility of primary HTLV-1 isolates from patients with HTLV-1-associated myelopathy to reverse transcriptase inhibitors.Viruses · 2011Article
- Inhibitors of strand transfer that prevent integration and inhibit human T-cell leukemia virus type 1 early replication.Antimicrobial agents and chemotherapy · 2008Article
- Treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis: toward rational targeted therapy.Neurologic clinics · 2008Review
- Effect of phosphonated carbocyclic 2'-oxa-3'-aza-nucleoside on human T-cell leukemia virus type 1 infection in vitro.Antimicrobial agents and chemotherapy · 2008Article
- Lamivudine resistance in human T-cell leukemia virus type 1 may be due to a polymorphism at codon 118 (V-->I) of the reverse transcriptase.Antimicrobial agents and chemotherapy · 2003Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effects of lamivudine (3TC) on in vitro infection of peripheral blood mononuclear cells (PBMC) from healthy donors with human T-cell lymphotropic virus type 1 (HTLV-1) were investigated. Direct measures of viral replication (viral DNA, RNA, and protein) all gave similar, very high 50% inhibitory concentrations in comparison with those previously reported for zidovudine. Nevertheless, 3TC inhibited HTLV-1-driven long-term growth of infected PBMC in vitro at concentrations (6.25 micro M) which had poor or no direct antiviral effects, suggesting that another mechanism may be playing a role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.